Identification of dimethyl 2,2’-((methylenebis(2-(2H-benzo[d][1,2,3]triazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)-6,1phenylene))bis(oxy))diacetate (TAJ4) as antagonist of NEK-Family: a future for potential drug discovery
Mubashir Aziz, Syeda Abida Ejaz, Pervaiz Ali Channar, Ali G Alkhathami, Tahir Qadri, Zahid Hussain, Mumtaz Hussaain, Rabail Ujan · 2024
Read Identification of dimethyl 2,2’-((methylenebis(2-(2H-benzo[d][1,2,3]triazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)-6,1phenylene))bis(oxy))diacetate (TAJ4) as antagonist of NEK-Family: a future for potential drug discovery by Mubashir Aziz, Syeda Abida Ejaz, Pervaiz Ali Channar, Ali G Alkhathami, Tahir Qadri, Zahid Hussain, Mumtaz Hussaain, Rabail Ujan (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11658429.txt.
Description
Mubashir Aziz and co-authors hunt a new blocker for three over-loud enzymes in cancers in a 2024 study of drug design. Gene reads show the three enzymes run high in breast, neck, and brain cancers in past data. High runs tie to worse life spans, which marks them as growth drivers in those ills.
That call gives cause to build a fresh blocker shaped to their sites in the cell. The new compound's form is the long name the title bears in full at the top. Body-pass and safety traits of the pick form part of the work, the team notes in the study.
Catalog record
| CREATOR | Mubashir Aziz, Syeda Abida Ejaz, Pervaiz Ali Channar, Ali G Alkhathami, Tahir Qadri, Zahid Hussain, Mumtaz Hussaain, Rabail Ujan |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 73 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |